CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,206,688 | +13.1% | 511,321 | -31.5% | 0.00% | +100.0% |
| Q2 2023 | $13,445,786 | +28.2% | 746,159 | +14.3% | 0.00% | 0.0% |
| Q1 2023 | $10,485,831 | +275.5% | 652,916 | +327.9% | 0.00% | – |
| Q4 2022 | $2,792,361 | +39.3% | 152,588 | +49.5% | 0.00% | – |
| Q3 2022 | $2,004,000 | -23.1% | 102,032 | -26.9% | 0.00% | – |
| Q2 2022 | $2,605,000 | +24.5% | 139,616 | +46.5% | 0.00% | – |
| Q1 2022 | $2,092,000 | +93.9% | 95,290 | +150.9% | 0.00% | – |
| Q4 2021 | $1,079,000 | -25.6% | 37,978 | -44.9% | 0.00% | – |
| Q3 2021 | $1,451,000 | -57.7% | 68,954 | -62.1% | 0.00% | – |
| Q2 2021 | $3,430,000 | +11.8% | 181,997 | -9.3% | 0.00% | – |
| Q1 2021 | $3,068,000 | +17.1% | 200,753 | +8.1% | 0.00% | – |
| Q4 2020 | $2,620,000 | +310.7% | 185,742 | +356.3% | 0.00% | – |
| Q3 2020 | $638,000 | -83.0% | 40,706 | -81.0% | 0.00% | -100.0% |
| Q2 2020 | $3,745,000 | +10914.7% | 213,821 | +9398.9% | 0.00% | – |
| Q1 2020 | $34,000 | -92.2% | 2,251 | -87.1% | 0.00% | – |
| Q4 2019 | $437,000 | +65.5% | 17,407 | -0.7% | 0.00% | – |
| Q3 2019 | $264,000 | +725.0% | 17,538 | +1260.6% | 0.00% | – |
| Q2 2019 | $32,000 | -52.2% | 1,289 | -56.8% | 0.00% | – |
| Q1 2019 | $67,000 | -81.6% | 2,982 | -75.5% | 0.00% | – |
| Q4 2018 | $365,000 | +3.4% | 12,183 | -1.2% | 0.00% | – |
| Q3 2018 | $353,000 | – | 12,336 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |